Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that an oral presentation of data for delafloxacin, its lead antibiotic candidate, will be given at the 20^th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, Institute for Clinical Pharmacodynamics, Ordway Research Institute. The presentation at ECCMID includes data from a Phase 2 study, completed in January 2009, which confirmed the appropriate clinical doses of delafloxacin for future clinical studies and demonstrated the efficacy of delafloxacin in complicated skin and structure infections (cSSSI) when compared to tigecycline.

“Population pharmacokinetics and pharmacokinetic-pharmacodynamic metrics for delafloxacin”

Oral Presentation:

• Abstract #O509: Tuesday, April 13, 2010, 12:06-12:18pm, "Population pharmacokinetics and pharmacokinetic-pharmacodynamic metrics for delafloxacin", Rubino, et.al., (Lecture Hall I/K)